The Governing Council of the University of Toronto

Other

Mcmaster University

Saksin Lifesciences Pvt. Ltd.

Modmab Therapeutics Corporation

Sidhu, Sachdev

Angers, Stephane

Moffat, Jason

Robitaille, Melanie

Jason Moffat

Sachdev Singh Sidhu

Guohua Pan

Amandeep Gakhal

Stephane Angers

Nish Patel

Helena Persson

Saravanan Sundararajan

Wei Ye

Jelena Tomic

Megan Elizabeth Mclaughlin

Melanie Robitaille

Edward Hartley Sargent

Shana Olwyn Kelley

Frederic Fellouse

Peter Aldridge

David Philpott

Barbara Mair

Sanna Masud

Cn Ramchand

Zachary Steinhart

Ravikant Harit

Reena Arora

Aju Antony

Santhi Vinodh

Jarrett Adams

Rashida Williams

Xiaoyu Zhang

Sheila K Singh

Parvez Vora

Chitra Venugopal

Xiaowei Wang

Elizabeth Megan Mclaughlin

Microfluidic devices, kits systems and methods are provided for high throughput phenotypic separation of magnetically labelled cell samples. The devices and methods can be used for example to sort cells based on level of target marker and to sort screen cells, such as CRISPR screen cells and other screens with a large number of target cells, to isolate target cells and putative genetic modifiers.

Microfluidic devices and methods of use

There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.

Molecular display system

The invention provides novel synthetic antibodies directed against VEGF and uses thereof.

Synthetic antibodies against VEGF and their uses

This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

CD133-binding agents and uses thereof

The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression or activity of Frizzled protein.

Frizzled5 protein-binding agents

This invention provides monoclonal antibodies that recognize one or more Frizzled receptors. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Antibodies against Frizzled receptor

Antibodies against frizzled receptor

Growing community of inventors

Toronto, Canada

Jason Moffat